Brind.
Part of Health Canada regulates the approval of generic pharmaceuticals, allowing market entry following patent expiration.

How could Sandoz's generic semaglutide approval affect Novo Nordisk?

Possible What happens if… A possibility worth considering, not a forecast.

Novo Nordisk may face reduced revenue from generic semaglutide entry into Canada Sandoz is seeking approval from Health Canada for a generic version of semaglutide, the active ingredient in Novo Nordisk's Ozempic. Following the patent expiration of Ozempic on January 4, the availability of cheaper generic options will increase supply and competition in the Canadian market. When the first generic version launches, it is priced at 75 per cent or 85 per cent of the brand-name list price, which could lead to reduced market exclusivity and revenue for Novo Nordisk.

Reported by 1 independent outlet Written Thursday
Effect
Strong negative
How direct
Brind's reasoning
When
Within months
The story
No new developments lately

How it reaches Novo Nordisk

Reported by news outletsBrind's reasoning

Tap any step to see the evidence behind it.

The facts so far

As reported. Each one links to where it comes from.

  • The market protections for Ozempic expired on Jan. 4.theglobeandmail.com
  • Sandoz applied to Health Canada to make generic semaglutide in late 2024.theglobeandmail.com
  • Health Canada did not approve the first generic until April 28.theglobeandmail.com
  • When the first generic version of an off-patent drug is launched, it is priced at 75 per cent or 85 per cent of the brand-name list price.theglobeandmail.com

Why it matters

For Novo Nordisk, the entry of a generic semaglutide directly challenges the market exclusivity of Ozempic, a blockbuster diabetes and obesity drug. This competition could lead to a significant reduction in market share and revenue for the Danish drug maker in Canada.

This situation is part of a larger trend in Canada, where more than 300 drugs will go off-patent in the next decade. Sandoz noted that without generic options, public and private payers would pay $183-billion on these drugs, but this could drop to $89-billion if cheaper off-patent drugs were promptly available.

What we don't know yet

  • How quickly will Health Canada approve Sandoz's generic semaglutide application?
  • What specific market share reduction is projected for Novo Nordisk once the generic is available?

What would change this answer

Health Canada accelerates its review process for generic submissionsThe generic semaglutide could hit pharmacy shelves sooner, increasing the timeline for Novo Nordisk's revenue impact.
Novo Nordisk successfully lobbies for regulatory barriers or price controlsThe market entry of the generic could be slowed or limited, mitigating the potential revenue loss.

Who else could feel it

Other possible ripples from the same event.

Reporting

Keep going

The full eventSandoz seeks Health Canada approval for generic semaglutide Everything aboutNovo Nordisk

Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.